CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study
Johannes Duell, Aleš Obr, Marinela Augustin, Jan Endell, Hao Liu, Sabine Geiger, Ian M. Silverman, Sumeet Ambarkhane, Andreas Rosenwald
Abstract
CD19 is an important target for novel anti-lymphoma treatments as it is broadly and homogenously expressed across many B-cell malignancies [1,2]. Approximately 30–50% of patients with diffuse large...
Topics & Concepts
LenalidomideCD19Diffuse large B-cell lymphomaLymphomaInternal medicineMedicineOncologyCancer researchMultiple myelomaPeripheral bloodCAR-T cell therapy researchLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research